Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 4/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4994448 | 0.86 | LPL (0.33) | LPLLIPG | |
| SCHEMBL4998784 | 0.83 | LPL (0.39) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL31030871 | 0.74 | LPL (0.43) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL2595567 | 0.74 | LPL (0.43) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL4789211 | 0.73 | LPL (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL20865722 | 0.72 | MEN1 (0.33) | LPLLIPG | |
| SCHEMBL2204718 | 0.71 | LPL (0.41) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL18189549 | 0.71 | AHR (0.43) | LPLLIPG | |
| SCHEMBL14758354 | 0.70 | MAPK1 (0.34) | LPLLIPG | |
| SCHEMBL2523103 | 0.70 | LPL (0.47) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371868-B2 | Processes for producing 7-isoindoline-quinolonecarboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-05-13 | — | — | US | disclosed |
| US-20070225506-A1 | PROCESSES FOR PRODUCING 7-ISOINDOLINE-QUINOLONECARBOXYLIC ACID DERIVATIVE AND ITS INTERMEDIATE, AS WELL AS SALT OF 7-ISOINDOLINE-QUINOLONECARBOXYLIC ACID DERIVATIVE, ITS HYDRATE AND COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20050203301-A1 | Processes for producing 7-isoindoline-quinolone carboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-09-15 | — | — | US | disclosed |
| US-6482835-B2 | SUCH AS (R)-1-CYCLOPROPYL-8-DIFLUOROMETHOXY-7-(1-METHYL-2,3-DIHYDRO-1H-5-ISOINDOLYL)-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXYL IC ACID METHANESULFONATE; CHEMICAL INTERMEDIATES; BACTERICIDES; CATALYSIS | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
| US-20020049328-A1 | Processes for producing 7-isoindoline-quinolonecarboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6337399-B1 | CONDENSATION OF ISOINDOLE WITH BORATE GROUP WITH QUINOLONE CARBOXYLIC ACID | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-01-08 | — | — | US | disclosed |
| EP-1031569-A1 | PROCESSES FOR PRODUCING 7-ISOINDOLINEQUINOLONECARBOXYLIC DERIVATIVES AND INTERMEDIATES THEREFOR, SALTS OF 7-ISOINDOLINEQUINOLONECARBOXYLIC ACIDS, HYDRATES THEREOF, AND COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049328-A1 | Processes for producing 7-isoindoline-quinolonecarboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | BRD7, IMPDH1, DDT | LPL 4625/4885LIPG 4868/4885CA1 1413/4885 |
| US-20050203301-A1 | Processes for producing 7-isoindoline-quinolone carboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | KCNQ2, CYP4X1, HAAO | LPL 4288/4885LIPG 4418/4885CA1 482/4885 |
| US-20070225506-A1 | PROCESSES FOR PRODUCING 7-ISOINDOLINE-QUINOLONECARBOXYLIC ACID DERIVATIVE AND ITS INTERMEDIATE, AS WELL AS SALT OF 7-ISOINDOLINE-QUINOLONECARBOXYLIC ACID DERIVATIVE, ITS HYDRATE AND COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | DHX15, HAAO, DHX35 | LPL 4072/4885LIPG 4322/4885CA1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.